Edition:
India

Altimmune Inc (ALT.OQ)

ALT.OQ on NASDAQ Stock Exchange Global Market

32.71USD
10:45pm IST
Change (% chg)

$7.71 (+30.84%)
Prev Close
$25.00
Open
$26.90
Day's High
$32.79
Day's Low
$25.64
Volume
2,870,139
Avg. Vol
711,615
52-wk High
$32.79
52-wk Low
$1.52

Select another date:

Thu, Jul 9 2020

BRIEF-Altimmune Signs Teaming Agreement With Dynport Vaccine Company

* ALTIMMUNE SIGNS TEAMING AGREEMENT WITH DYNPORT VACCINE COMPANY ON U.S. GOVERNMENT FUNDING EFFORTS FOR ITS COVID-19 VACCINE CANDIDATE, ADCOVID™

BRIEF-Altimmune Announces Dosing Of First Patient In Phase 1B Clinical Trial Of Nasoshield

* ALTIMMUNE ANNOUNCES DOSING OF FIRST PATIENT IN PHASE 1B CLINICAL TRIAL OF NASOSHIELD™, A SINGLE DOSE INTRANASAL ANTHRAX VACCINE CANDIDATE Source text for Eikon: Further company coverage:

BRIEF-Altimmune Receives Award From U.S. Department Of Defense To Fund Phase 1/2 Clinical Trial Of T-Covid In Outpatients With Early Covid-19

* ALTIMMUNE RECEIVES AWARD FROM U.S. DEPARTMENT OF DEFENSE TO FUND PHASE 1/2 CLINICAL TRIAL OF T-COVID™ IN OUTPATIENTS WITH EARLY COVID-19 Source text for Eikon: Further company coverage:

BRIEF-Venrock Healthcare Capital Partners II LP Reports A 20.8% Stake In Altimmune Inc As Of June 15

* VENROCK HEALTHCARE CAPITAL PARTNERS II LP REPORTS A 20.8% STAKE IN ALTIMMUNE INC AS OF JUNE 15, 2020 - SEC FILING

BRIEF-Altimmune Announces IND Clearance For Phase 2 Trial Of Heptcell

* ALTIMMUNE ANNOUNCES IND CLEARANCE FOR A PHASE 2 TRIAL OF HEPTCELL™ IMMUNOTHERAPEUTIC FOR THE TREATMENT OF CHRONIC HEPATITIS B

BRIEF-Altimmune Launches Trial Of T-COVIDTM For Patients With Early Covid-19

* ALTIMMUNE LAUNCHES CLINICAL TRIAL OF T-COVIDTM, AN INVESTIGATIONAL INTRANASAL IMMUNE MODULATOR FOR THE TREATMENT OF PATIENTS WITH EARLY COVID-19

BRIEF-Altimmune Posts Q1 Loss Per Share $0.26

* ALTIMMUNE ANNOUNCES FIRST QUARTER 2020 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE

BRIEF-Altimmune Appoints Former Pfizer Executive Diane Jorkasky To Board Of Directors

* ALTIMMUNE APPOINTS FORMER PFIZER AND GSK EXECUTIVE DIANE JORKASKY, M.D. TO ITS BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

BRIEF-Altimmune Inc - Prospectus Supplement Is Only Offering Shares Of Common Stock Of Up To $18.9 Million

* ALTIMMUNE INC - PROSPECTUS SUPPLEMENT IS ONLY OFFERING SHARES OF COMMON STOCK HAVING AN AGGREGATE OFFERING PRICE OF UP TO $18.9 MILLION - SEC FILING

BRIEF-Altimmune Completes First Development Milestone Toward A Single-Dose Intranasal Covid-19 Vaccine

* ALTIMMUNE COMPLETES FIRST DEVELOPMENT MILESTONE TOWARD A SINGLE-DOSE INTRANASAL COVID-19 VACCINE

Select another date: